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Abstract
Background
The costimulatory CD40-CD40L pathway plays a role in kidney inflammation. We have pre-
viously reported that renal CD40 upregulation precedes cellular interstitial infiltrate and fibro-
sis in the unilateral ureteral obstruction (UUO) model. Here we sought to evaluate whether
the administration of siRNA-CD40 has a therapeutic effect in a reversible unilateral ureteral
obstruction (D-UUO) mice model.
Methods
Eight week-old C57BL6J male mice were divided into four groups: Vehicle (Phosphate-buff-
ered saline) (n = 8); siRNA SC (non-specific siRNA) (n = 6); siRNA-CD40 (n = 8) and WT
(wild type) (n = 6) mice. UUO was performed with a microvascular clamp. At day 3 after sur-
gery, the ureteral clamp was removed and nephrectomy of the contralateral kidney was per-
formed. Immediately, PBS, siRNA SC (50μg) or siRNA-CD40 (50μg) was administrated via
the tail vein. Mice were killed 48h hours after the siRNA or saline administration. Wild type
(WT) mice were used as controls. Blood samples were collected for measuring creatinine
and blood urea nitrogen (BUN). Histology and kidney mRNA expression were performed.
Results
The administration of siRNA-CD40 reduced significantly the severity of acute renal failure
associated with UUO. Pathologic analysis showed reduction of tubular dilation, interstitial
fibrosis, F4/80 macrophage and CD3 (T cell) infiltration in animals treated with siRNA-
CD40. Furthermore, kidney mRNA gene expression analysis showed significantly lower lev-
els of macrophage markers (F4/80 and Mannose receptor), fibrosis matrix proteins (Fibro-
nectin, MMP-9, Collagen IV and α-SMA), pro-inflammatory cytokines (iNOS and MCP-1)
and the pro-fibrotic molecule TGF-β1 in siRNA-CD40.
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Conclusions
The administration of siRNA-CD40 therapy reduces the severity of the acute kidney injury
induced by obstructive uropathy and promotes kidney repair. This strategy seems suitable
to be tested in humans.
Introduction
Obstructive nephropathy is a clinical syndrome resulting from structural and functional
changes of urinary tract which is a common cause of Chronic kidney disease[1].
Renal interstitial fibrosis is the final pathway of obstructive nephropathy and is the major
pathological basis studied[2]. Although not reversible at the late stage, renal interstitial fibrosis,
which may have great significance in the prognosis of the disease, can be ameliorated and
renal function could be improved provided with early and timely diagnosis and treatment[3].
The UUO (unilateral ureteral obstruction) model is the most classical used inducing renal
fibrosis since most of them are irreversible[4]. However, the D-UUO (reversible unilateral ure-
teral obstruction) is a model that has been used to study the structural and functional recovery
of the kidneys after relief of the obstruction and has much future potential for the study of
inflammatory and immune processes, cellular and tissue regeneration because is a model simi-
lar to what occurs in the clinic[5,6]. But, only a few models have been described and the tech-
nique requires significant surgical expertise[7–9].
CD40 is a co-stimulatory molecule that belongs to the tumor necrosis factor superfamily.
The CD40/CD40L dyad participates in T-cell proliferation and in effector functions[10]. It is
expressed in many cell types, including epithelial tubular, endothelial, immune cells; and plays
a role in kidney inflammation[11].
CD40-CD40L blockade using gene silencing strategies as a siRNA (small inhibitory RNA),
have demonstrated its effectiveness therapeutic effects in several renal models: ischemia-reper-
fusion injury, acute allograft rejection, atherosclerosis, and autoimmune inflammatory pro-
cesses[12–15]. Thus, CD40 has become a new emerging target[16].
Furthermore, because macrophages are recruited to local sites of the inflamed kidney and
are critical during the inflammatory response, they are an ideal target for therapies[17]. In a
previous study, our group reported that kidney pro-inflammatory genes such as CD40 were
upregulated and precedes macrophage interstitial infiltrate and fibrosis in the UUO model
[18].
In the present study, we hypothesized that blocking the co-stimulatory CD40-CD40L sig-
naling by siRNA-CD40 (small inhibitory RNA anti-CD40) administration would reduce the
inflammatory response and kidney damage in the obstructive nephropathy. Thus, in this study
we sought to evaluate the therapeutic effect of siRNA-CD40 in kidney injury induced by
obstructive nephropathy in a D-UUO mice model.
Materials and methods
Ethics statement and animals
Eight-weeks-old C57BL/6J male mice were purchased from Janvier (Laval, France), initial
body weight of 21–26 g. Mice were monitored daily for body weight and were housed in
groups of four per cage at constant temperature of 21 ± 2˚C, with a 12 h-light/12 h-dark cycle
and 55 ± 2% of humidity. They were given water and standard chow ad libitum.
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All experiments were carried out in accordance with the Guidelines of the European Com-
munity Committee on Care and Use of Laboratory Animals and Good Laboratory Practice.
The study complied with the current legislation on animal experiments in the European
Union, and the principles of laboratory animal care were approved by the ethics committee for
animal research of UB-Bellvitge (496/16).
CD40-siRNA design
CD40 was silenced with a specific siRNA-CD40 in mice. Global patterns of expression of
mRNAs in the obstructive kidney were compared among siRNA-CD40, siRNA SC (scrambled,
non-specific siRNA), PBS (Vehicle) and wild type (WT) non-treated mice. The siRNA-CD40
sequence used in this study has been previously described by our group (siRNA TNFRSF5-3)
[19]. It consists of a 21-nucleotides sense strand and antisense strand resulting in a two nucleo-
tides overhang at the 30 end of the antisense strand (sense 50-GUGUGUUACGUGCAGUGACUU-
30, antisense 30-GTCACACAAUGCACGUCACUG-50). SC was used with a non-specific siRNA
for off-target effects. The synthesis was carried out by an external manufacturer (Microsynth,
Switzerland). To generate siRNAs from RNA single strands, equimolar amounts of comple-
mentary sense and antisense strands were mixed and 100% annealed. Oligonucleotides strands
were annealed as previously described[15].
Surgical technique and experimental design
C57BL/6J male mice were divided into four groups: Vehicle, animals with Phosphate-buffered
saline (PBS) (n = 8); siRNA SC, animals with a non-specific siRNA (n = 6); siRNA-CD40, ani-
mals with specific siRNA anti-CD40 (n = 8) and WT, mice without any type of surgery or
treatment administration served as control (n = 6). Fig 1 describes the study model with the
following steps:
- UUO operation (UUO day 1). UUO was performed under continuous inhalated iso-
fluorane/oxygen anesthesia (2%). Mice received a pre-operative dose of analgesia (0.15 mg/kg
buprenorfine, subcutaneously). The abdominal wall was opened doing a midline laparotomy
and whereby the bowel gently displaced to one side. The right ureter was exposed and clamp-
ing with a one plastic microvascular clamp for vein vessel of 0.2–1 mm with atraumatic jaws
(BIOVER). The bowel was then laid back in place and muscle and skin were then closed with
sterile surgical of 4–0 nylon (B. Braun, Melsungen, Germany).
- Deobstruction, nephrectomy of the contralateral kidney and siRNA administration
(UUO day 3). At day 3 after clamping surgery, the ureteral clamp was removed and nephrec-
tomy of the contralateral kidney was performed (D-UUO model). Immediately, PBS, 50μg of
siRNA SC or siRNA-CD40 were administrated via the tail vein. The follow-up was 48 hours.
- Postoperative care. During the 6h postoperative period, normal activity (grooming,
feeding, drinking, etc.) was monitored and the surgical wound and abdominal palpation were
examined to rule out systemic infection. Mice tolerated the two surgeries without difficulty as
evidenced by a rapid return to normal activity after recovery from anesthesia. There was no
evidence of any adverse events.
- Samples. Renal function was assessed by measuring serum creatinine and blood urea
nitrogen (BUN) following Jaffe’s and GLDH reactions (Olympus Autoanalyzer AU400, Ham-
burg, Germany) in the Veterinary Clinical Biochemistry Laboratory at Universitat Autònoma
de Barcelona. Blood samples were extracted prior to UUO surgery (UUO d1), prior to deob-
struction and nephrectomy (UUO d3), 24 hours (D-UUO d1) and 48 hours (D-UUO d2) after
deobstruction and nephrectomy in all groups (Fig 1B). Blood was obtained on day 3 prior to
surgery to avoid major aggression to the mice.
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Mice were killed 48 hours after deobstruction and nephrectomy of the contralateral kidney
under anesthesia via a heart puncture (blood collection). Kidney specimens were taken for his-
tological and gene expression mRNA analysis.
Fig 1. Scheme of the experimental design for the four groups of studied mice. (A) WT and groups 1 (Vehicle), group 2 (siRNA SC) and group 3 (siRNA
CD40) where the D-UUO was performed with the administration of Vehicle, siRNA SC or siRNA CD40. (B). Blood samples were obtained at days UUO d1,
UUO d3, D-UUO d1 and D-UUO d2.
https://doi.org/10.1371/journal.pone.0215232.g001
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Optical microscopy, immunohistochemistry
Mice kidneys were removed under anesthesia and they were rapidly decapsulated and chopped
into 2–3 mm small pieces. Renal slices were fixed in 10% (vol./vol.) formalin and embedded in
paraffin. All pieces contained both cortex and medulla. Histological cross sections of 3μm
thickness were stained with H&E (Haematoxylin & Eosin), Sirius Red, Masson Trichrome, α-
SMA (1:100, Thermo Scientific, CA, USA,), F4/80 (1:50, LabClinics, Barcelona, Spain) and
CD3 (1:150, Abcam, Cambridge, UK) for optical microscopy assessment. Histological sections
were stained as described previously[20].
Sirius Red, Masson Trichrome, α-SMA, F4/80 and CD3 staining were quantified using
Image J software in each non-overlapping cortical field from the cortical region. A magnifica-
tion of 100x was used to evaluate the degree of renal injury. Red, brown and blue staining were
considered as positive. Scores from 5 fields per kidney sections (10 per animal) were averaged
and mean scores were quantified. Values are obtained as relative stained area (%). Pathological
evaluation of tubular dilation was graded as follows: 0, no dilation; 1, changes affect <25%; 2,
changes affect between 25–50% and 3, changes affect >50%. Cells located in the interstitial
area were analyzed in 10 fields in each sample and assessed using Image J software. The per-
centage of CD3 positive cells was evaluated scoring total number of cells followed by manual
counting of the number of CD3 positive cells per field. Immunostained sections without pri-
mary antibodies were used as negative control.
Quantitative real-time PCR
RNA was extracted from kidney with PureLink RNA Mini Kit (Invitrogen, CA, USA) as
previously described[20]. A total amount of 400 ng RNA was used to perform the reverse tran-
scription using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, War-
rington, UK). Thermal cycling conditions were 10 min at 25ºC, 120 min at 37ºC, 5 min at
85ºC and finally held at 4ºC. The mRNA expression levels of TGF-β1 (transforming growth
factor- β1), CD40, MCP-1 (monocyte chemotactic protein-1), IL-2, Cytokeratin-18, iNOS
(inducible nitric oxide synthase), Fibronectin, MMP-9 (Matrix metallopectidase 9), MR (Man-
nose receptor), F4/80, MCSF (Macrophage Colony Stimulating Factor), Collagen IV and α-
SMA were quantified by TaqMan real-time PCR (ABI Prism 7700, Applied Biosystems, Wal-
tham, USA) using the comparative 2-(delta)(delta)Ct method (Applied Biosystems).
Statistical analysis
All data are reported as mean ± SE. Group means were compared with either the Student’s t
test or ANOVA for parametric values, or the Mann-Whitney U test or Krustal-Wallis test for
non-parametric values. For semiquantitative variables the Chi-squared test was used. P� 0.05
was considered to be statistically significant. All statistical analyses were carried out using Stat-
View software.
Results
Acute kidney injury
First, as seen in Fig 2, the siRNA SC and Vehicle groups showed worse renal function com-
pared to siRNA CD40 treated mice. In all groups, there was evidence of acute kidney injury,
with higher creatinine and BUN levels compared to its baseline values and reaching maximum
values at day 1 after declamping and the nephrectomy of the contralateral kidney (D-UUO
d1). Subsequently, creatinine levels decreased tending to normalization demonstrating the
validity of the D-UUO model. BUN levels showed parallel results.
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Second, siRNA-CD40 treated group showed significantly lower levels of creatinine and
BUN compared to the others groups. Thus, siRNA-CD40 administration reduced significantly
the severity of acute renal failure associated with UUO (Fig 2).
Fig 2. Renal Function analysis. (A) Creatinine and (B) Blood Urea Nitrogen (BUN) analysis. In all groups, both
creatinine and BUN levels significantly increased showing maximum values at day 1 post clamp release (D-UUO d1)
compared to the non-treated animals (WT). siRNA-CD40 treated group showed lower levels of creatinine and BUN
reflecting a fast recovery of the renal function. ANOVA test; data are means ± SE, �p� 0.05 vs WT, +p� 0.05 vs
siRNA-CD40.
https://doi.org/10.1371/journal.pone.0215232.g002
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Kidney tubular damage and inflammatory infiltration
Histology analysis. At day 3 of obstruction (UUO d3), tubular dilation was clearly
observed. Tubular epithelial cells showed vacuolar degeneration together with partial renal
tubular lumen expansion. Once the clamp was removed, from day 1 to 2 after deobstruction
(D-UUO d1 and D-UUO d2 respectively), pathological lesions were significantly ameliorated.
Renal lesions caused by UUO and in particular tubular dilation were significantly attenuated
at day 2 after deobstruction, especially in animals treated with siRNA-CD40 compared to oth-
ers groups (Fig 3).
Inflammatory cell infiltration evaluated by F4/80 macrophage and CD3 T cell population,
was significantly increased at day 3 of obstruction. Once the clamp was removed (D-UUO d1
and D-UUO d2), we observed the amelioration of the inflammatory response. Macrophage
interstitial infiltration was significantly reduced in animals treated with siRNA-CD40 (Fig 4A).
Furthermore, lymphocytic infiltration was also significantly decreased in siRNA CD40 treated
mice compared to SC and vehicle groups (Fig 4B).
Renal Interstitial fibrosis
Interstitial fibrosis was observed in the obstructed kidneys at day 3 as shown by collagen
deposition in the interstitium analyzed by Sirius Red and Masson Trichrome staining.
Moreover, there was widespread expression of α-SMA in the interstitium adjacent to the
dilated tubules of the obstructed kidneys, which indicated the presence of interstitial myo-
fibroblasts. After removing the clamp, the collagen deposit and α-SMA-positive signals were
significantly decreased. In comparison with the other groups, the administration of siR-
NA-CD40 significantly reduced the interstitial fibrosis associated with the obstructive uropa-
thy (Fig 5).
Fig 3. Tubulo-interstitial damage evaluation of the obstructed kidneys. Representative images of Haematoxylin & Eosin (H&E) staining. Original
magnification 100x. Graphical quantification of H&E from each group using tubular dilation analysis. Chi-squared test; the values represent the mean ± SE,
�p� 0.05 vs D-UUO d2, +p� 0.05 vs D-UUO d2+siRNA SC.
https://doi.org/10.1371/journal.pone.0215232.g003
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Kidney gene expression
As observed in Fig 6, CD40 mRNA expression was significantly increased in the vehicle group.
The administration of siRNA-CD40, as expected, was associated with a significant reduction
of renal CD40 mRNA expression compared to the vehicle group. In parallel, pro-inflammatory
Fig 4. Renal inflammatory cell infiltration in the obstructed kidney. (A) Representative images of macrophage interstitial infiltration (F4/80
staining) and (B) CD3 positive T cell infiltration. Original magnification 100x. Values are represented in graphical quantification and are obtained
as relative stained area (%). Both macrophages and T cells showed a decrease in infiltration after siRNA-CD40. ANOVA test; values are
means ± SE, �p� 0.05 vs D-UUO d2+Vehicle, +p� 0.05 vs D-UUO d2+siRNA SC.
https://doi.org/10.1371/journal.pone.0215232.g004
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cytokines such as MCP-1 and iNOS were clearly reduced with the siRNA-CD40 administra-
tion. Pro-fibrotic cytokine such TGF-β1, showed significantly lower levels after siRNA-CD40
administration regarding the others groups. Besides, significant reduction of macrophage
markers such as F4/80 and Mannose receptor; fibrosis matrix proteins such as Fibronectin,
Fig 5. Interstitial fibrosis evaluation of the obstructed kidneys. (A) Representative images of α-SMA (B) Sirius
Red and (C) Masson’s trichrome staining. Original magnification 100x. Graphical quantification of α-SMA, Sirius
Red and Masson’s Trichrome from each group. Values are obtained as relative stained area (%). ANOVA test; values
are means ± SE, �p� 0.05 vs D-UUO d2+Vehicle, +p� 0.05 vs D-UUO d2+siRNA SC.
https://doi.org/10.1371/journal.pone.0215232.g005
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MMP-9, Collagen IV and α-SMA were observed after the administration of siRNA-CD40.
Interestingly the cytokeratin-18 was up-regulated with siRNA-CD40 therapy (Fig 6).
Discussion
In this work, we have investigated the progression of obstructive nephropathy lesions in the
D-UUO mouse model in which CD40 expression was silenced “in vivo” with a specific siRNA.
Our study demonstrates that siRNA-CD40 ameliorates the renal inflammation and fibrosis
induced by UUO renal injury.
Fig 6. Gene expression profile of the obstructed kidney. For all qRT-PCR analysis, all data are compared to wild type
levels. Evaluation of macrophage markers, fibrosis matrix proteins, pro-inflammatory and pro-fibrotic genes after the
administration of siRNA-CD40. ANOVA test; values are means ± SE, �p� 0.05 vs D-UUO d2+Vehicle, +p� 0.05 vs
D-UUO d2+siRNA SC.
https://doi.org/10.1371/journal.pone.0215232.g006
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CD40, a marker of pro-inflammatory cytokines, plays a crucial role in the onset and main-
tenance of the inflammatory reaction, and it is expressed by most immune cells as well as by
other nonimmune cells such as tubular epithelial cells, where play a critical role in the patho-
genesis of renal inflammatory response [21],[22].
Interaction of CD40 with its ligand stimulates downstream signaling and has been targeted
in many disorders by using selective pharmacological inhibitors[16]. In this sense, our group
has previously demonstrated that a specific CD40 siRNA was effective in reducing CD40 tissue
expression[14], while promoting an anti-inflammatory blockade of several transcriptional
gene networks in endothelial cells[23].
siRNA are small molecules filtered in the kidney, so kidney disease is a good target to this
kind of process. Therapies using siRNA have being developed for various kidney clinical con-
ditions, but few studies have primarily been used to treat obstructive nephropathy[24]. In the
present work, UUO increases CD40 expression significantly and a specific siRNA was admin-
istrated in a systemic CD40 silencing strategy and the reduction in the inflammation and fibro-
sis lesions was confirmed. A possible explanation for this powerful anti-inflammatory effect
may be an attenuated production of the chemokines and adhesion molecules necessary for
interstitial inflammation to occur, since a reduction in the number of plaque-infiltrating F4/80
or macrophages, CD40 cells and cytokines was observed.
In the present study, interstitial macrophage and lymphocyte infiltration, renal tubule dila-
tion, renal myofibroblast expansion, and collagen fiber deposition were all observed. After the
release of the obstruction, all these were declined nearly to basal levels. The administration of
siRNA-CD40 was associated with a significant reduction of renal CD40 mRNA expression
regarding D-UUO and siRNA SC groups. Furthermore, kidney mRNA gene expression analy-
sis showed significantly lower levels of pro-inflammatory and pro-fibrotic cytokines after siR-
NA-CD40 administration. These results together indicate that there is an increase of the pro-
inflammatory and pro-fibrotic environment within the kidney following obstructive injury
with subsequent decrease after de-obstruction, and with greater reduction after siRNA-CD40
administration that translates in a significant reduction in the severity of acute renal failure
assessed by serum creatinine.
TGF-β1 is considered the most critical factor in the pathogenesis of renal interstitial fibrosis
and can be found in a variety of Chronic kidney disease[25]. Moreover, renal interstitial fibro-
blasts are the major effector cells contributing to EMT (epithelial-mesenchymal transition),
collagen is a major component of extracellular matrix, and α-SMA is one of the most impor-
tant proteins in the EMT process, and its expression in activated EMT would be substantially
increased[26,27]. In this experiment, we observed significantly increased TGF-β1 and α-SMA
expression in the obstructed kidney, which was more reversed after treatment with
siRNA-CD40.
This early reversibility is explained because fibrosis appears on the third day of obstruction
and is established at 7 days where remain for longer time[28]. The duration of UUO and the
extent of cell loss play a pivotal role in the recovery of GFR (glomerular filtration rate) and sub-
sequent renal remodeling and repair. UUO for >72h may lead to renal fibrotic and apoptotic
changes culminating in a permanent decrease in GFR. It have been demonstrated that relief of
the obstruction after two to five days permits recovery of renal structure and function[29].
Whereas in this reversible UUO model of three days obstruction no advanced fibrosis changes
has been developed yet for the rapid decrease of dynamic factors that develop fibrosis.
Besides, we observed that siRNA-CD40 treatment resulted in decreased macrophage and
lymphocyte infiltration into tubulointerstitial areas after renal injury. Macrophage accumula-
tion correlates closely with the progression of renal disease and, importantly, systemic macro-
phage depletion alleviates renal injury and renal interstitial fibrosis after UUO[17].
Therapeutic effect of siRNA-CD40 in reversible obstructive nephropathy
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Matrix metalloproteinase-9 (MMP-9) was previously thought to be anti-fibrotic due to
their ability to induce extracellular matrix remodeling. However, it has also been recognized
that is involved in the initiation and progression of kidney fibrosis and it can also exert pro-
fibrotic effects under various pathological conditions. The exact mechanism by which MMP-9
contributes to renal fibrosis still is a matter of debate. We have previously reported in a UUO
murine model, that MMP-9 expression was significantly reduced when an anti-inflammatory
macrophage cell therapy was performed[18]. The MMP-9 result in this article is in line with
our previous results but also with those reported by Tan et al suggesting that MMP-9 contrib-
utes to the pathogenesis of renal fibrosis in UUO via macrophage recruitment[30].
The apparent discrepancy between maximal damage and normal serum creatinine at day 3
is justified by the presence of the contralateral kidney. At this time, we performed ureter deob-
struction and contralateral nephrectomy and therefore all the renal function relied on the
recovery of the de-obstructed kidney. This is the reason why the creatinine value peaked at
24h post de-clamping.
The cytokeratin-18 is a specific marker of renal tubular epithelial cell integrity[31]. The
administration of siRNA CD40 significantly increased the expression of this cytokeratin-18 in
kidney tissue. This result was in line with histologic amelioration and the reduction of several
pro-inflammatory and pro-fibrotic genes. These results suggested that mice treated with
siRNA CD40 better preserved the structural integrity of their kidney tissue.
The irreversible model of UUO is a most traditional model for renal fibrosis induction but
is not focused upon the intrinsic cell biology of the kidney following reversal UUO, so it is not
ideal to study this type of treatment[8,9,32]. Moreover, in our study, contrary to others revers-
ible models described[29,33], the contralateral kidney was removed, leaving the previous
obstructed kidney as a life sustaining organ, which was very important to test the true efficacy
of the siRNA-CD40. In order to discard an unspecific silencing effect, we used and scrambled,
non-specific siRNA. This group was similar to vehicle for the majority of results, including
renal function, cell infiltration and fibrosis. Indeed, CD40 siRNA provided a significant thera-
peutic effect in comparison to both vehicle and SC siRNA control groups.
Thus, siRNA-CD40 is a novel signaling pathway mediating the fibrogenic effect delaying
the process of CKD and could be a new therapeutic target. These initial results open the door
to clinical trials silencing CD40 not only in the UUO inflammatory response, but also in other
autoimmune and inflammatory diseases where CD40 have a key role.
In conclusion, the present study demonstrated: First, that the expression of CD40 was
inhibited by siRNA-CD40 delivered in a D-UUO mice model with strongest inhibitory effi-
cacy. Second, the administration of siRNA-CD40 therapy reduces the severity of the acute kid-
ney injury induced by obstructive uropathy and promotes kidney repair representing a novel
alternative therapeutic strategy. Third, the D-UUO model described here is a simple, well-tol-
erated, reproducible and more reliable method, since it includes the nephrectomy of the con-
tralateral kidney. Offers to explore the induction and resolution of kidney inflammation
together with key aspects of tissue repair post injury at a cellular and molecular level.
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